Bigger Regulatory Challenges in Diagnostics Than in Therapeutics, Industry Expert Says
Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorafenib in AML
Improved Cancer Care Through Innovation
Payers Look to CER for Improved Healthcare Decisions
Data Show High Response Rate to Ibrutinib Combination for Patients With Hard-to-Treat MCL
Results Project Savings for Payers With Novel Oral Anticoagulants
SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML
CML Updates: Defining MMR and Results of the DASISION Trial
Sessions Report Phase 2 Results of Pomalidomide Combinations
Promising Results for Elotuzumab Presented in Session on Multiple Myeloma
Early Treatment, Monoclonal Antibodies Discussed in Multiple Myeloma
ASH Presents Second Round of Tests, Treatments to Question Under Choosing Wisely Initiative
Care Plans to Reduce Healthcare Utilization in Sickle Cell Disease
Poster Presentations Cover Therapeutic Options in CML
Healthcare Costs in Need of Solutions: Experts at ASH Agree
Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma
Ibrutinib Demonstrates Significant Responses for Patients With Hard-to-Treat CLL/SLL, Phase 2 Data Show
Study Suggests Method of Reducing Blood Clots Without Risking Bleeding
